0 -Diindolylmethane (DIM) is a promising anticancer agent derived from Brassica vegetables, but the mechanisms of DIM action are largely unknown. We have shown that DIM can upregulate the expression and stimulate the secretion of interferon-gamma (IFNc) in the human MCF-7 breast cancer cell line. This novel effect may provide important clues to explain the anticancer effects of DIM because it is well known that IFNc plays an important role in preventing the development of primary and transplanted tumors. Utilizing promoter deletions, we show here that the region between À108 and À36 bp in the IFNc promoter, which contains two conserved and essential regulatory elements, is required for DIM-induced IFNc expression. DIM activates both JNK and p38 pathways, induces the phosphorylation of c-Jun and ATF-2, and increases the binding of the homodimer or heterodimer of c-Jun/ATF-2 to the proximal AP-1 . CREB-ATF-binding element. Moreover, studies with specific enzyme inhibitors showed that up-stream Ca 2 þ -dependent kinase(s) is required for the inducing effects of DIM in MCF-7 cells. These results establish that DIM-induced IFNc expression in human breast tumor cells is mediated by activation of both JNK and p38 pathways, which is ultimately dependent on intracellular calcium signaling.
Introduction
Interferon-gamma (IFNg) is a cytokine that plays an important role in modulating innate and adaptive immune responses. The absence of IFNg production or cellular responsiveness in human and experimental animals significantly compromises their ability to generate an effective immune response against microbial infection. Recently, IFNg has been shown to prevent development of primary and transplanted tumors (Ikeda et al., 2002) . Several mechanisms have been proposed for IFNg action, including (a) effects on tumor growth/survival, (b) angiostasis in tumors, and (c) effects on both the innate and adaptive immune responses against tumors. Normally, IFNg production occurs predominantly in a limited number of cell types, including lymphocytes and natural killer cells. The expression of IFNg mRNA in other cell types occurs at very low levels, and secreted protein is generally not detected. The lack of endogenous IFNg expression in many cell types results from gene silencing by DNA methylation, the expression of silencer DNA-binding proteins, or the lack of T-cell/NKcell-specific nuclear DNA-binding proteins that are induced by specific extracellular signals (Young and Ghosh, 1997) .
3,3 0 -Diindolylmethane (DIM), a major in vivo product of acid-catalysed oligomerization of indole-3-carbinol (I3C), is a promising antitumor agent derived from Brassica vegetables. Several studies have demonstrated that dietary exposure to DIM has a pronounced effect against tumor development, especially in estrogenresponsive tissues (Wattenberg and Loub, 1978; Grubbs et al., 1995; Chen et al., 1998) . In addition, I3C and DIM apparently have become the most popular adjunct therapies for recurrent respiratory papillomatosis (RRP) because of their effectiveness and low level of toxicity (Auborn, 2002; Wiatrak, 2003) . Thus, there is considerable interest in the modes of action of DIM because of its pronounced antitumor activities in rodents and humans.
Results of several studies in our laboratories showed that DIM exhibited a biphasic response on proliferation of cultured breast tumor cells. DIM, in the higher concentration range, inhibited proliferation and induced apoptosis in a manner that was independent of estrogen receptor status (Cram et al., 2001; Hong et al., 2002a, b; Firestone and Bjeldanes, 2003) . Interestingly, in the lower concentration range, DIM induced proliferation of estrogen receptor-replete MCF-7 cells and activated DNA binding of the estrogen receptor by a mechanism that was independent of ligand binding to the receptor (Riby et al., 2000) . Thus, since apparently nonphysiological concentrations are required for the antiproliferative effects of DIM and lower concentrations induce cell proliferation, the clearly antitumor effects of DIM appear to require modes of action in addition to the direct cytostatic effects on tumor cells.
In continued studies of DIM function, we found that this indole could induce IFNg gene expression and stimulate the secretion of IFNg into the medium in the MCF-7 cells (unpublished data). To confirm and extend this unusual observation, we report here an analysis of DIM activation of IFNg transcription. We determined that a region of the core promoter (À108 to À36) is responsible for gene activation by DIM. The results showed further that DIM induced the phosphorylation of c-Jun and ATF-2 and increased the binding of the homodimer or heterodimer of c-Jun/ATF-2, and CREB to the proximal AP1 Á CREB-ATF-binding element. These effects are mediated ultimately by activation of calcium signaling via the JNK and p38 pathways.
Results

DIM upregulates IFNg expression in MCF-7 human breast cancer cells
The effect of DIM on IFNg gene expression in MCF-7 cells was examined by RT-PCR analyses. RT-PCR measurements ( Figure 1a ) using GAPDH as an internal control indicated that DIM induced time-dependent increases in IFNg transcript levels. A maximum induction of 6.8-fold was reached after 6 h relative to vehicletreated controls. Levels of IFNg protein in the cell culture medium were significantly increased from undetectable levels to approximately 50710 pg/ml following incubations with DIM for 24 h (unpublished data). DIM also increased the expression of IFNg gene in MDA-MB-231 cells (up to 16-fold), an estrogenindependent cell line (Figure 1b) , as well as Jurkat T cells (up to fourfold), a well-established lymphocyte cell line (Figure 1c ). These results confirm our previous findings and show that the effect of DIM is neither cellspecific nor ER-dependent.
Both the proximal and distal elements in the IFNg core promoter are required for the inducing effects of DIM To determine whether DIM activates the human IFNg promoter, we transiently transfected MCF-7 cells with different chloramphenicol acetyltransferase (CAT) reporter gene constructs with progressive deletions of the human IFNg promoter. As shown in Figure 2a , the CAT activity driven by the promoter fragments À538 to À36 (pIFN-538) and the deletions À339 to À36 (pIFN-339) and À108 to À36 (pIFN-108) were all significantly activated by DIM treatment, whereas the normal basal induction of the parental pBL2CAT vector was unchanged. These data indicate that DIM-responsive elements were present in the promoter fragment À108 to À36 bp of the IFNg gene. To further characterize the mechanism by which DIM stimulates the activity of the IFNg core promoter, four different constructs were used in the transfection assays (Figure 2b ). The plasmids 3 Â (À66/À47)CAT and 3 Â (À96/À75)CAT contain three copies of the regions IFNg/À66 to À47 bp (5 0 -TTGTGAAAATACGTAATCC-3 0 ) and IFNg/À96 to À75 bp (5 0 -GCCTATCTGTCACCATCTCATC-3 0 ). The plasmid (À108/À36)wt contains the wild-type sequence of the IFNg promoter; the plasmid (À108/À36) Mechanism of interferon-gamma induction by DIM L Xue et al mutant contains mutations in both proximal and distal elements. The activities of both CAT reporters, 3 Â (À66/À47)CAT and 3 Â (À96/À75)CAT, were significantly increased by DIM treatment, although their activities were much less than the reporter (À108/ À36)wt. The simultaneous site mutation of these two DNA-binding elements completely blocked DIMmediated activation of the IFNg promoter. These results indicate that the proximal and distal elements identified in the first 108 bp of the IFNg promoter weakly respond individually to DIM exposure, but exhibit a strong synergistic response when configured in close proximity as they are in the proximal IFNg promoter. Mechanism of interferon-gamma induction by DIM L Xue et al (Penix et al., 1993 (Penix et al., , 1996 . We used Western blot analyses to examine the effects of DIM on the levels of these transcription factors and their phosphorylated derivatives. Results in Figure 4a showed that the levels of total protein for CREB, ATF-2, and a-tubulin did not change on exposure to the indole. The level of total c-Jun, however, exhibited a transient increase to a maximum by 6 h of exposure and then decreased to the control level by 24 h. Results of analysis of the phosphorylated proteins shown in Figure 4b indicated that treatment with DIM induced strong but transient increases in phosphorylation of c-Jun and ATF-2 that peaked at 2 h of treatment. The results also showed a slightly increased level of phosphorylation of CREB and ATF-1 at 2 h. These results indicate that DIM treatment strongly activated the phosphorylation of the c-Jun and ATF-2 transcriptional factors, but had little effect on the levels of phospho-CREB and phospho-ATF-1.
DIM induces binding of c-Jun, ATF-2 and CREB to the proximal element
The identities of the nuclear proteins that bind in response to DIM treatments to the proximal element were examined by electrophoretic mobility shift assay (EMSA). Results in Figure 5a showed that the densities of complexes 1 and 2 were significantly increased by DIM treatment, which were completely blocked by excess unlabeled wild-type IFNg proximal probe, but not affected by excess unlabeled mutant proximal probe. To characterize the DNA-protein complexes, unlabeled Cre and AP-1 oligonucleotides were used as competitors in EMSA. The Cre oligonucleotide completely blocked the formation of both complexes 1 and 2 and the AP-1 oligonucleotide partially competed for complex 1 (Figure 5a , lanes 5 and 6). Together, these results indicate the presence of CREB/ATF-1 and AP-1 proteins in complexes formed with the proximal element.
To confirm this result and to identify the specific factors contained within each complex, antisera specific for the various transcriptional factors were added to the binding reactions. Antibody to CREB/ATF-1 proteins blocked the formation of complex 2, confirming that this band contains CREB/ATF-1 family proteins ( Figure 5b Taken together, these results confirm that the transcription factors, CREB, c-Jun, and ATF-2, bind to the IFNg proximal element. Upon DIM treatment, cJun and ATF-2 are activated and bind as a homodimer or heterodimer to DNA.
Overexpression of dominant-negative c-Jun and ATF-2, and wild-type CREB transcription factors blocks DIM-induced activation of IFNg core promoter
The results indicated that the c-Jun, ATF-2, and CREB transcription factors may be involved in the DIMinduced transcriptional activation of IFNg in MCF-7 cells. To further examine this possibility, the effects of added wild-type and dominant-negative transcription factors were tested in cotransfection assays ( Figure 6 ). Transfection of cells with expression plasmids for the dominant-negative c-Jun with mutant DNA-binding domain (c-JunDBR) and the dominant-negative ATF2 mutant containing only the DNA-binding domain (ATF2BR) markedly inhibited the DIM-induced activities of the IFNg core promoter in a manner that was dependent on the concentration of the dominantnegative construct (Figure 6b and d) . However, wildtype c-Jun and ATF-2 had little effect on the promoter activities (Figure 6a and c) . In contrast, transfection of cells with a wild-type CREB expression vector had an inhibitory effect on DIM-induced expression from the core promoter (Figure 6e ), whereas the DNA-binding mutant kCREB had no significant effect (Figure 6f ). These results suggest that the c-Jun/ATF2 homodimer or heterodimer and CREB have opposing effects on the IFNg core promoter: increased levels of the c-Jun/ATF2 clearly activated transcription of IFNg, whereas increased level of CREB decreased DIM-induced IFNg transcription.
DIM specifically activates JNK and p38 signal transduction pathways
Phosphorylation of c-Jun or ATF-2 within their NH 2 -terminal transactivation domains correlates well with enhanced transactivating activity. The stress-activated protein kinases (SAPKs)/c-Jun NH 2 -terminal kinases (JNKs) are the dominant kinases responsible for c-Jun phosphorylation. Furthermore, the JNK and p38 kinase families can phosphorylate ATF-2 at thr-69 and ser-71 in the transactivation domain. To assess the effect of DIM on JNK and p38 activation, analysis of MAPK phosphorylation was performed by Western blots. Results in Figure 7 indicated that DIM treatment (30 min to 4 h) induced strong but transient increases in phospho-JNKs and phospho-p38s, and a rapid and sustained increase in phospho-ERKs. Peak induction of phospho-JNKs and phospho-p38s of more than 20-fold compared to controls occurred at 1-2 h of DIM 
Blockade of JNK and p38 pathways ablates DIM induction of IFNg-transcription
To further demonstrate the roles of JNK and p38 pathways in the activation of IFNg gene expression, we examined the effect of specific pharmacological inhibitors and dominant-negative forms of MAPK on the inducing effects of DIM. We used the pIFN-108 reporter construct as the indicator of IFNg gene expression. As shown in Figure 8a , SP600125, a selective inhibitor for JNKs (Dalton et al., 1993) , and SB203580, a selective inhibitor for p38s (Dighe et al., 1994) , significantly inhibited IFNg promoter activity induced by DIM, whereas PD98059, an inhibitor for ERKs (Farrar and Schreiber, 1993; Yin et al., 2004) , had no significant effect. In contrast, we observed that H-89, a selective inhibitor for PKA (Kaplan et al., 1998; GarciaFernandez et al., 2003) , the kinase primarily responsible for phosphorylation of CREB, synergistically increased the activity of the DIM-induced IFNg promoter. The dominant-negative forms of MKK3 and MKK6, which are upstream regulators of p38s, MKK4, which is an upstream regulator of JNKs, and JNK2, significantly reduced the induction of IFNg promoter activity. However, a dominant-negative form of MKK1, which is an upstream regulator of ERK, did not significantly affect the DIM-induced IFNg promoter activity (Figure 8b ).
We also examined the effects of the specific inhibitors on the expression of DIM-induced endogenous IFNg expression (Figure 8c) . SP600125, the inhibitor for JNKs, or SB203580, the inhibitor for p38s, strongly decreased the expression of IFNg induced by DIM, and 5 mg) was transfected into MCF-7 cells, which were then pretreated with 50 mM PD98059, or 25 mM SP600125, or 10 mM SB203580, or 10 mM H89 for 30 min and then treated with DMSO or 50 mM DIM for 24 h. (b) Indicated dominant negative expression plasmid (0.1 mg)/empty vector and 0.5 mg of pIFN-108 were cotransfected into MCF-7 cells, which were then treated with DMSO or 50 mM DIM for 24 h. CAT activity was expressed as the fold induction relative to DMSO controls. (c) Effects of specific inhibitors on DIM-induced endogenous IFNg gene expression in MCF-7 cells. Total RNA was isolated from MCF-7 cells, which were pretreated with 25 mM SP600125, or 10 mM SB203580, or 10 mM SB202190 for 30 min and then treated with DMSO or 50 mM DIM for another 6 h. IFNg expression level was expressed as fold induction relative to the DMSO-treated control after normalized to GAPDH. Asterisks indicate significant difference relative to DIM-treated controls (Po0.05)
Mechanism of interferon-gamma induction by DIM
L Xue et al SB202190 (Alsayed et al., 2001) , the inhibitor for both JNKs and p38s, completely abolished the expression of IFNg, which confirmed that both JNK and p38 pathways are required for DIM-induced expression of endogenous IFNg.
Inhibition of Ca 2 þ -dependent pathways significantly blocks the DIM-induced effect on IFNg transcription
Increased intracellular Ca 2 þ concentration and activation of protein kinase C (PKC) are required for IFNg expression in T lymphocytes (Crabtree and Clipstone, 1994; Isakov and Altman, 2002) . To investigate whether these signals are required for DIM-induced JNK and p38 activation and IFNg expression in MCF-7 cells, we examined the effects of inhibitors of PKC and Ca 2 þ -dependent pathways on expression of the pIFN-108 reporter construct. Results shown in Figure 9a indicated that treatment with four different PKC inhibitors, GF109203X (Kiang et al., 1999) , Go¨6983 (Cui et al., 2003) , Calphostin C (Rosfjord et al., 1999) , and Chelerythrine (Mueller et al., 1997) , did not affect the inducing effect of DIM on IFNg transcription. GF109203X and Go¨6983 are general inhibitors of cPKC and nPKC kinase activities. Calphostin C and Chelerythrine are pan-PKC inhibitors by interacting with the regulatory domain or the catalytic domain of PKC respectively. However, cotreatment with BAPTA (Kiang et al., 1999) , a Ca 2 þ chelator, or CsA (Ogretmen and Safa, 1996) , an inhibitor of calcineurin, significantly blocked the inducing effects of DIM (Figure 9b ). Both inhibitors significantly reduced the DIM-induced phosphorylation of c-Jun and ATF-2 (data not shown). These data indicate that Ca 2 þ -triggered pathways are the ultimate regulators of DIM-induced IFNg expression in MCF-7 cells.
Discussion
Our results indicate that DIM can increase the transcription of the IFNg gene in human breast cancer MCF-7 cells by a mechanism that is mediated by activation of JNK and p38 pathways via initial stimulation of calcium-dependent pathways. The DNA region between À108 and À36 bp in the IFNg promoter is required for DIM-induced IFNg expression and contains two conserved and essential elements. Results of the EMSA and cotransfection experiments indicate that DIM-induced transcription of the IFNg gene results in part from the activation of c-Jun and ATF-2, and the binding of c-Jun to the conserved element as a homodimer or as a heterodimer with ATF-2. CREB was confirmed to be a negative regulator of IFNg expression since increased levels of this transcription factor reduced the effects of DIM. By using selective kinase inhibitors, we determined further that JNK and p38 pathways, which are induced by DIM treatment, are involved in the DIM-induced IFNg gene expression in MCF-7 cells. Moreover, we further showed that Ca 2 þ -triggered pathways are upstream regulators in this process.
In the present study, we demonstrated that DIM could induce IFNg gene transcription in MCF-7 cells, MDA-MB-231 cells, as well as in Jurkat T cells. To our knowledge, this is first report that IFNg expression could be induced in human breast cancer cell lines. It is known that IFNg is predominantly produced by natural killer (NK) cells during the early stages of immune responses, and by T cells during the adaptive stages of immune responses (Kasahara et al., 1983a, b) . Besides NK cells and T cells, additional cell populations have been reported to express very low levels of IFNg mRNA, including B-cell lines, fibroblasts, and macrophages (Benjamin et al., 1986; Pang et al., 1992; McCaffrey et al., 1993; Dimarzio et al., 1994; Rady et al., 1995) . The physiological relevance of IFNg expression in these cell types is unclear, and little work has been done to characterize the control of IFNg transcription in nonimmune cells. In the current study, we identified that the region between À108 and À36 bp of the IFNg promoter, which is necessary and sufficient to confer activation-specific and cyclosporin-sensitive IFNg expression in T cells (Chrivia et al., 1990; Penix et al., 1993) , is responsible for DIM-induced IFNg gene transcription in MCF-7 cells. There are two essential Figure 9 DIM-induced activity of IFNg promoter is dependent on Ca 2 þ -triggered pathways. In all, 0.5 mg of the reporter, pIFN-108, was transfected into MCF-7 cells, which were then pretreated with 1 mM GF109203X, 0.1 mM Go¨6983, 1 mM Calphostin C, 10 mM Chelerythrine (panel a), 30 mM BAPTA, or 1 mM CsA (panel b) for 1 h and treated with DMSO or 50 mM DIM for 24 h. CAT activity was expressed as the fold induction over DMSO controls. Results were expressed as the mean value (X þ s.d.) of at least three individual experiments. Asterisks indicate significant difference relative to DIM-treated controls (Po0.05) and conserved regulatory elements, À96 to À75 (distal) and À66 to À47 (proximal), in this region (Penix et al., 1993) , and both of them are required for full DIM-induced expression of IFNg in MCF-7 cells.
It is of interest that IFNg expression is strongly induced when cells, including MCF-7 cells, are treated with cycloheximide to inhibit protein synthesis. The mechanism has not been further investigated and is presumably due to abrogation of expression of silencer DNA-binding proteins, such as Yin-Yang-1 (YY1) (Ye et al., 1996) or DNA methyltransferase, which regulates the level of DNA methylation (Chrivia et al., 1990; Laird and Jaenisch, 1994) . Using this conventional experimental technique, we could not directly test for the possible requirement of protein synthesis in the response to DIM. However, the CAT reporter gene construct (pIFN-108), which contains only the IFNg promoter fragment À108 to À36, responded to DIM treatment, but not to cycloheximide treatment. Using this construct, we proved that the effect of DIM on IFNg expression is direct as cotreatment of cells with the protein synthesis inhibitor did not block the inducing effect of DIM. This indicates that de novo protein synthesis is not required for the effect of DIM on IFNg expression. Thus, gene activation results in part from the large increase in phosphorylation of existing c-Jun and ATF-2.
The results from the EMSA and cotransfection experiments indicate that transcriptional activation of IFNg follows in part from the activation of c-Jun and ATF-2, and binding of phospho-c-Jun to the proximal promoter element either as a homodimer or as a heterodimer with phospho-ATF-2. Supporting this interpretation are our observations of the inhibitory effects of the dominant-negative c-Jun and ATF-2, which blocked DIM-induced transcription from the reporter construct, pIFN-108. Increased levels of phospho-c-Jun and phospho-ATF-2, and activation of JNKs and p38s, were further confirmed by Western blot. These results are consistent with a report by Wilson and co-workers, who found that cotransfection of dominantnegative c-Jun inhibited PMA/ionomycin-induced IFNg promoter activity in Jurkat T cells (Penix et al., 1996) . In these published studies, however, cotransfection with two different types of dominant-negative ATF-2 had no effect on IFNg promoter function (Penix et al., 1996) . This difference in our results compared to the published studies suggests that different mechanisms of IFNg gene activation are operative in the two cell lines.
In this study, we identified that three MAPK pathways, ERKs, JNKs, and p38s, could be activated by DIM, which is consistent with the study done by Sun et al. They reported that DIM could induce a luminal endoplasmic reticulum (ER) stress response in a cervical cancer cell line, C33A, and activation of JNK pathway was observed in this process (Sun et al., 2004) . The disruption of ER Ca 2 þ homeostasis is one of the mechanisms that can cause ER stress (Nakagawa et al., 2000) . The downstream components of ER stress pathways may contribute to cytotoxic effects of DIM. One possibility is that DIM-induced eIF2a phosphorylation results in a general cessation of protein synthesis and impairs the synthesis of key regulatory proteins necessary for cell proliferation (Sun et al., 2004) . In this study, we provided another mechanism that DIMinduced IFNg expression through activation of JNK and p38 pathways may contribute to the cytotoxic effects of DIM. These effects are mediated ultimately by activation of calcium signaling. Although the consensus mammalian ER stress response element (ERSE) (CCAAT(N9)CCACG, with N being a strikingly GCrich region of 9 bp) is not found in the IFNg promoter, it is possible that downstream components of the ER stress pathway are involved in the DIM-induced IFNg expression.
DIM has been demonstrated to induce cell-cycle arrest and apoptosis in human breast and prostate cancer cells, which is independent of p53 pathway (Ge et al., 1996; Nachshon-Kedmi et al., 2003) . DIM can induce apoptosis in breast cancer cells by a process that is mediated by the modulated expression of the Bax/Bcl-2 family of apoptotic regulatory factors (Hong et al., 2002a) . DIM also induces apoptosis in prostate cancer cells through the mitochondrial pathway by increasing cytochrome c release and activation of caspases (Nachshon- Kedmi et al., 2004) . IFNg has been reported to induce cell-cycle arrest and p53-independent apoptosis in a variety of cancer cell lines (Ossina et al., 1997; de Veer et al., 2001; Chawla-Sarkar et al., 2003) . Induction of apoptosis involves the bcl-2 family and caspases (Awasthi and Wagner, 2004; Burchert et al., 2004) . It has been reported that IFNg increased Bax-to-Bcl-2 protein ratio in murine lens epithelial alphaTN4-1 cells (Awasthi and Wagner, 2004) and induced caspase 8 transcript in a variety of cell lines, such as MCF-7 and MDA-MB-231 breast carcinoma (Ruiz-Ruiz et al., 2000) . This evidence indicates that DIM-induced apoptosis may be mediated by IFNg or IFNg-stimulated genes.
Our results show further that DIM-induced IFNg expression in MCF-7 cells is distinct from the mechanism of T-cell receptor-mediated IFNg activation in T lymphocytes. It is well established that induction of IFNg gene transcription in T lymphocytes is mediated by activation of the T-cell receptor, which leads to phospholipase C-g1 (PLC g1)-mediated hydrolysis of membrane inositol phospholipids and subsequent production of inositol phosphates and diacylglycerol (DAG). These two second messengers increase intracellular Ca 2 þ concentration and activate PKC (Crabtree and Clipstone, 1994; Isakov and Altman, 2002) . The increased intracellular calcium concentration leads to the activation of calcineurin phosphatase activity, which dephosphorylates and activates the nuclear factor of activated T cells (NFAT) family of transcription factors (Clipstone and Crabtree, 1992; Horsley and Pavlath, 2002) . Increases in both intracellular calcium concentration and PKC activation are necessary for IFNg induction in T lymphocytes. In contrast, we showed here that PKC activation is not required for DIMinduced IFNg expression in MCF-7 cells. Cotreatment with PKC inhibitors had no effect on DIM function.
Four different PKC inhibitors were used in this assay to exclude the possibility that some PKC isoforms may be involved. Blockade of calcium signaling by either the Ca 2 þ chelator, BAPTA, or an inhibitor of calcineurin, cyclosporin A, totally blocked DIM function. It is important to point out, however, that activation of calcium signaling may not be sufficient for DIMinduced IFNg activation in MCF-7 cells since known calcium activators, such as ionomycin, do not activate IFNg expression in this system. It is likely that activation of additional pathways is required for DIM induction of IFNg as well.
Taken together, these results collectively support the mechanistic model indicated in Figure 10 to explain DIM-induced activation of IFNg transcription in MCF-7 cells. In the resting cells, which have increased levels of repressor proteins, such as phospho-CREB, and decreased levels of activator proteins, such as phospho-cJun and phospho-ATF-2, IFNg gene transcription is silenced because of a dominant-negative influence from the repressor proteins. DIM induces IFNg transcription in a Ca 2 þ -dependent manner, which is mediated by the activation of JNK and p38 pathways. The mechanism of JNK and p38 activation via Ca 2 þ -dependent pathways remains unclear, but is likely to be mediated by the small G protein, Rac, which is upstream of both JNK and p38. IFNg gene activation occurs when CREB is displaced from the IFNg promoter by the homodimer or heterodimer of c-Jun/ATF-2.
In summary, DIM is a novel immunomodulator, which can activate IFNg gene expression in both breast cancer cells and Jurkat T cells in a manner that is dependent on Ca 2 þ -dependent kinase activities, but independent of PKC activation. Further studies of the initial signaling events that are triggered by DIM are in progress in our laboratories.
Materials and methods
Cell lines and Regents
The human breast adenocarcinoma cell lines MCF-7 and MDA-MB-231 and Jurkat T cells, obtained from the American Type Culture Collection (ATCC, Maryland, USA), were grown as adherent monolayers in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% heat-inactivated fetal bovine serum, 3.0 g/l of glucose, 3.7 g/l of sodium bicarbonate, in a humidified incubator at 371C and 5% CO 2 , and passaged at approximately 80% confluence.
The following antibodies to transcription factors and MAP kinases were used. Rabbit polyclonal antibodies against CREB (C-21), ATF2 (C-19), c-Jun (N), c-Fos (4), and mouse monoclonal antibodies against phosphorylated ATF2 (F-1) and c-Jun (KM-1) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The antibody against phosphorylated CREB/ATF-1 was from Upstate Biotechnology. The polyclonal antibodies against JNK, p38, p44/p42, phospho-JNK, phospho-p38, and phospho-p44/p42 were from Cell Signaling Technology.
Cyclosporin A and BAPTA were purchased from Sigma Chemical Co. (St Louis, MO, USA). PD98058 was purchased from Tocris (Ellisville, MO, USA). Go¨6983, GF109203X, Calphostin C, Chelerythrine, SB203580, SB202190, SP600125, and H-89 were purchased from Calbiochem (San Diego, CA, USA).
RT-PCR
Following the indicated treatment, total RNA was isolated as described previously (Hong et al., 2002a) and reverse transcribed into cDNA using the Superscript Preamplification System (Gibo BRL). Briefly, 10 mg of total RNA was reverse transcribed at 371C for 1 h using oligo dT in a 50 ml reaction mixture. The resultant cDNA (2.5 ml) was subjected to PCR (941C for 45 s, 571C for 1 min, 721C for 1.5 min) using specific primers synthesized by Genosys (Woodlands, TX, USA). The sequences of primers were as follows: IFNg-1, 5 0 -GCAGAGC CAAATTGTCTCCT, IFNg-2, 5 0 -ATGCTCTTCGACCTC GAAAC (Csiszar et al., 2000) ; GAPDH-1, 5 0 -ACCACAGTC CATGCCATCAC, GAPDH-2, 5 0 -TCCACCACCCTGTTG CTGTA; CAT-1, 5 0 -CGGCATCAGAGCAGATTGTA, CA T-2, 5 0 -AACGTCGTGACTGGGAAAAC. Amplified products were visualized following electrophoresis on a 1.5% agarose gel with ethidium bromide staining. Band intensities were scanned and quantitated using the NIH Image program, and the ratio of IFNg or CAT to GAPDH was plotted.
Plasmid constructs
The different deletions of the IFNg promoter pIFN-538, pIFN-339, pIFN-108 (Penix et al., 1993) , and plasmids containing wild-type human ATF-2 (ATF-2FL), a truncated form lacking the transcriptional activation domain (ATF-2BR) (Abdelhafiz et al., 1992) , wild-type c-Jun (Abate et al., 1991; Kerppola and Curran, 1993) , and the plasmid containing c-Jun with a deletion of residues 260-266 in the DNA-binding domain (c-JunDBR) (Gentz et al., 1989) were kindly provided by Dr Christopher B Wilson (Department of Pediatrics and Immunology, University of Washington). The plasmids 3 Â (À66/À47)CAT, 3 Â (À96/À75)CAT, (À108 to À36)CAT (wild-type sequence), and (À108 to À36)DD 0 CAT (containing the mutations for the two AP-1 Á CREB-ATF-binding sites) (Cippitelli et al., 1995) were kindly provided by Dr Howard A Young (National Cancer Institute Frederick Cancer Research and Development Center, Maryland, USA). The plasmids wild-type CREB and dominant-negative kCREB (Walton et al., 1992; Lazennec et al., 2001) were kindly provided by Dr Richard H Goodman (Oregon Health Sciences University).
DNA transfection and CAT assay
DNA transfection was carried out using Lipofectamine (Gibco BRL) as described previously (Riby et al., 2000) . Briefly, MCF-7 cells were washed twice with PBS and 2 ml of Opti-MEM medium was added to each plate. The CAT reporter DNA (0.5 mg) and 8 ml of Lipofectamine were diluted to 200 ml of Opti-MEM medium, incubated at room temperature for 30-45 min and added to each plate. In cotransfection experiments, the indicated amounts of expression plasmids containing transcription factor cDNAs under the control of the RSV promoter were also included. The total amount of RSV vector was kept constant by the addition of control pRcRSV plasmid lacking a cDNA insert. After 5-6 h, 2 ml of fresh medium containing 10% FBS was added. After treatment for 24 h, the transfected cells were harvested and CAT activity was determined as described previously (Riby et al., 2000) .
Gel mobility shift assay
Nuclear extracts were prepared by lysis of three near-confluent (80-90%) cultures of MCF-7 cells for each treatment, as described (Cippitelli et al., 1995) . The nuclear proteins (15 mg) were incubated with radiolabeled DNA probes in a 20-ml reaction mixture containing 20 mM Tris (pH 7.5), 60 mM KCl, 2 mM EDTA, 0.5 mM dithiothreitol, 1.8 mg of poly(dI-dC), and 4% Ficoll. In some cases, the indicated amount of doublestranded oligomer was added as a cold competitor, and the mixture was incubated at room temperature for 10 min prior to adding the DNA probe. In supershift analysis, the antisera were added to the binding reaction, and the mixture was incubated for 30 min at room temperature prior to adding the labeled DNA probe. The mixtures were analysed by a pre-run, nondenaturing 4.0% polyacrylamide gel. The gel was dried and autoradiographed.
Western blot analysis
Following the indicated treatment, cells were harvested in lysis buffer (10 mM Tris, 150 mM NaCl, 0.1%. SDS, 1% deoxycholate, 1 mM EDTA, 1% Nonidet P-40) with protease inhibitors (10 mg/ml leupeptin, 20 mg/ml aprotinin, 1 mg/ml pepstatin, 1 mM phenylmethylsulfonylfluoride, 1 mM dithiothreitol, 1 mM sodium fluoride, 1 mM Na 3 VO 4 , 10 mM b-glycerophosphate). Total cellular protein (100 mg) was fractionated by electrophoresis on 15% polyacrylamide, 0.1% SDS resolving gels, and electrically transferred overnight to nitrocellulose membranes (Millipore, Bedford, MA, USA). Membranes were blocked with 5% nonfat milk in wash buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.05% Tween 20) for 1 h and incubated with antibodies overnight at 41C. Membranes were subsequently washed and incubated for 1 h with HRP-linked secondary antibody. Proteins were visualized by the enhanced chemiluminescence system from Amersham Pharmacia Biotech.
Statistical analysis
The statistical differences between groups were determined using ANOVA and Tukey's Studentized range test. The level of significance are noted at the level of Po0.05. The results are expressed as means þ s.d. for at least three replicate determinations for each assay.
Abbreviations
DIM, 3,3
0 -diindolylmethane; I3C, indole-3-carbinol; IFNg, interferon-gamma; DMSO, dimethylbenzanthracene; PMA, phorbol 12-myristate 13-acetate; CsA, cyclosporin A; CN, calcineurin; BAPTA, 1,2-bis(o-aminophenoxy)ethane-N,N, N 0 ,N 0 -tetraacetic acid tetra(acetoxymethyl) ester; MAPK, mitogen-activated protein kinase; ERK, extracellular signalregulated kinase; JNK, c-Jun N-terminal kinase; PKC, protein kinase C; PKA, protein kinase A; CAT, chloramphenicol acetyltransferase; EMSA, electrophoretic mobility shift assay; Sp1, promoter-specific transcription factor 1; Sp3, promoterspecific transcription factor 3; ER, endoplasmic reticulum.
